One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Abstract

The rate of RSV hospitalization in high-risk infants in Latin America was low and aligned with those observed in randomized control trials and observational studies. Palivizumab prophylaxis appeared effective and had a good safety profile in this population.